Intangible Assets

CPHI appears to have limited evidence of durable brand or proprietary-intangible pricing power, while peers with stronger regulated or specialty-pharma franchises typically sustain better margin resilience.

The provided TTM ROIC of -10.8% and ROCE of -11.8% indicate that any intangible advantage is not currently translating into economic returns, which is weaker than peers with proven monetization of IP or brand.

No peer-defensible evidence of patents, regulatory exclusivity, or differentiated formulation control was provided, so the company looks more replicable than peers with protected product portfolios.

Absent visible customer willingness to pay a premium, the company’s intangible assets do not appear to support durable retention or pricing power versus stronger branded or IP-backed competitors.

Switching Costs

The business does not show clear switching frictions that would lock customers in, whereas peers with validated formulations, contracts, or embedded workflows can retain accounts more effectively.

Negative ROIC and low asset turnover suggest customers are not tied to a high-value, hard-to-replace offering that would preserve margins through price increases.

No evidence of long-term contracts, regulatory requalification burdens, or integration dependencies was provided, so switching costs appear materially below peers with sticky distribution or platform relationships.

Because customers can likely substitute alternative suppliers without major operational disruption, retention appears more price-sensitive than in stronger-moat peer models.

Network Effects

CPHI does not appear to benefit from a self-reinforcing user, data, or ecosystem loop, unlike peers in platforms or distribution networks where scale attracts more participants.

The available metrics do not indicate that higher usage improves product value, lowers acquisition cost, or increases customer lock-in, which are the core mechanisms of network effects.

No evidence of a peer-dependent ecosystem, marketplace, or installed-base flywheel was provided, so the company lacks the structural compounding seen in networked competitors.

As a result, network effects do not currently contribute meaningfully to pricing power, retention, or long-run margin durability versus peers.

Cost Advantage

The negative ROIC and ROCE suggest CPHI is not converting operations into a cost position that beats peers on a durable basis.

Asset turnover of 0.09 is very low, which implies weak capital productivity rather than a structural cost edge over more efficient competitors.

No evidence of scale purchasing, manufacturing efficiency, or logistics advantages was provided, so any cost position appears insufficient to offset peer competition.

Without a demonstrable unit-cost advantage, the company is unlikely to defend margins against peers that operate with better throughput or lower overhead.

Efficient Scale

The company does not appear to operate in a niche where one or two players can serve the market efficiently enough to deter entry, unlike peers in highly concentrated regulated segments.

Negative returns and low turnover indicate that scale is not currently translating into a defensible operating footprint or superior economics.

No evidence of capacity constraints, regulatory barriers, or market concentration was provided to show that additional scale would materially weaken peer competition.

Because the market appears contestable rather than naturally monopolistic, efficient-scale protection looks weak relative to peers with more concentrated demand or infrastructure-like economics.

Overall Score

CPHI’s moat appears weak versus peers because the available evidence shows negative capital returns, low asset productivity, and no clear proof of protected IP, switching costs, network effects, cost leadership, or efficient-scale advantages that would sustain pricing power or retention over 5–10 years.